Newsgroup: it.salute
Titolo: Morti causate da chemioterapici a 30 giorni dalla 1 somministrazione , studio.

 
30-day mortality after systemic anticancer treatment for breast and lung cancer
in England: a population-based, observational study.
 
Michael Wallington, BA†, Emma B Saxon, PhD†, Martine Bomb, PhD, Rebecca
Smittenaar, PhD, Matthew Wickenden, BSc, Sean McPhail, PhD, Jem Rashbass, PhD,
David Chao, FRCP, John Dewar, FRCR, Prof Denis Talbot, PhD, Michael Peake, FRCP,
Prof Timothy Perren, MD, Charles Wilson, MD, Prof David Dodwell, MD.
 
Lancet Oncology, 17: 1023-1216, 2016.
 
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30383-7/abstract
 
 
 
Summary
 
Background
 
30-day mortality might be a useful indicator of avoidable harm to patients from
systemic anticancer treatments, but data for this indicator are limited. The
Systemic Anti-Cancer Therapy (SACT) dataset collated by Public Health England
allows the assessment of factors affecting 30-day mortality in a national
patient population. The aim of this first study based on the SACT dataset was to
establish national 30-day mortality benchmarks for breast and lung cancer
patients receiving SACT in England, and to start to identify where patient care
could be improved.
 
Methods
 
In this population-based study, we included all women with breast cancer and all
men and women with lung cancer residing in England, who were 24 years or older
and who started a cycle of SACT in 2014 irrespective of the number of previous
treatment cycles or programmes, and irrespective of their position within the
disease trajectory. We calculated 30-day mortality after the most recent cycle
of SACT for those patients. We did logistic regression analyses, adjusting for
relevant factors, to examine whether patient, tumour, or treatment-related
factors were associated with the risk of 30-day mortality. For each cancer type
and intent, we calculated 30-day mortality rates and patient volume at the
hospital trust level, and contrasted these in a funnel plot.
 
Findings
 
Between Jan 1, and Dec, 31, 2014, we included 23?228 patients with breast cancer
and 9634 patients with non-small cell lung cancer (NSCLC) in our regression and
trust-level analyses. 30-day mortality increased with age for both patients with
breast cancer and patients with NSCLC treated with curative intent, and
decreased with age for patients receiving palliative SACT (breast curative: odds
ratio [OR] 1·085, 99% CI 1·040–1·132; p<0·0001; NSCLC curative: 1·045,
1·013–1·079; p=0·00033; breast palliative: 0·987, 0·977–0·996; p=0·00034; NSCLC
palliative: 0·987, 0·976–0·998; p=0·0015). 30-day mortality was also
significantly higher for patients receiving their first reported curative or
palliative SACT versus those who received SACT previously (breast palliative: OR
2·326 99% CI 1·634–3·312; p<0·0001; NSCLC curative: 3·371, 1·554–7·316;
p<0·0001; NSCLC palliative: 2·667, 2·109–3·373; p<0·0001), and for patients with
worse general wellbeing (performance status 2–4) versus those who were generally
well (breast curative: 6·057, 1·333–27·513; p=0·0021; breast palliative: 6·241,
4·180–9·319; p<0·0001; NSCLC palliative: 3·384, 2·276–5·032; p<0·0001). We
identified trusts with mortality rates in excess of the 95% control limits; this
included seven for curative breast cancer, four for palliative breast cancer,
five for curative NSCLC, and seven for palliative NSCLC.
 
Interpretation
 
Our findings show that several factors affect the risk of early mortality of
breast and lung cancer patients in England and that some groups are at a
substantially increased risk of 30-day mortality. The identification of
hospitals with significantly higher 30-day mortality rates should promote review
of clinical decision making in these hospitals. Furthermore, our results
highlight the importance of collecting routine data beyond clinical trials to
better understand the factors placing patients at higher risk of 30-day
mortality, and ultimately improve clinical decision making. Our insights into
the factors affecting risk of 30-day mortality will help treating clinicians and
their patients predict the balance of harms and benefits associated with SACT.
 
Funding
 
Public Health England.
 
 
-- 
LO Staff - 
www.curenaturalicancro.com
 
lostaf...@doctor.com
 

 wrote:
 
Ho una notizia buona, e diverse cattive.
 
La prima notizia cattiva è che il titolo che metti in italiano non ha niente a che
vedere con l'argomento dello studio che citi. Non basta, che in inglese ci sia una
parola come "death" e "chemotherapy" per concludere che si parli dei morti causati
dai chemioterapici.
 
Per esempio "The death of chemotherapy pioneer Edwin Jarres in a car accident" :-)
 
La seconda notizia cattiva è che mi trovo d'accordo con l'impostazione e anche con
le conclusioni di quello studio. Il che vuol dire che non ti conveniva citarlo ;-)
 
Ma c'è una notizia buona, una volta tanto! Contento? Leggendo lo studio, si ricava
una conclusione (mi spiace: non è "la chemio uccide!111!1!undici!") che, almeno su
un punto, per una volta ti dà ragione!
 
Le ultime due notizie cattive sono che tu di sicuro non sai il perché, o quale sia
questo punto, perché evidentemente non hai capito di cosa parla lo studio (vedi il
titolo che hai messo, appunto); e che io non te lo spiegherò perché sono malvagio.
 
Leonardo
-- 
 
A terrible beauty is born.
                                     - W. B. Yeats, Easter 1916


wrote:
 
 
So what!? The question is: WHY was it necessary to use chemotherapy?
 
And do not forget: Hamer is a mass murderer!
 
http://www.deathsect.com
 

Homöopathie ist nichts als Hütchenspielerbetrug und organisierte Kriminalität
http://ariplex.com/folia/archives/565.htm
 
http://ariplex.com/folia/archives/570.htm
 
http://ariplex.com/folia/archives/585.htm
 
http://ariplex.com/folia/archives/643.htm
 
http://ariplex.com/folia/archives/647.htm